Qelbree was the largest of Supernus Pharmaceuticals, Inc.’s 9 reported lines in fiscal 2025, at $304.65M — 42% of $718.95M.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trokendi Xr | $261.22M | $94.34M | $63.20M | $42.42M | ||||||
| Qelbree | $61.32M | $140.19M | $241.27M | $304.65M | ||||||
| Gocovri | $104.42M | $119.64M | $130.82M | $146.82M | ||||||
| Oxtellar Xr | $115.35M | $113.40M | $99.46M | $40.70M | ||||||
| Apokyn | $75.31M | $75.08M | $73.93M | $47.77M | ||||||
| Collaboration Revenue (Zurzuvae) | — | — | — | $53.00M | ||||||
| Royalty, Licensing, & Other Revenues | — | $33.59M | $24.12M | $39.42M | ||||||
| Royalty, Licensing & Other Revenues | $17.81M | — | — | — | ||||||
| Other | $31.82M | $31.28M | $29.01M | $26.91M | ||||||
| Onapgo | — | — | — | $17.25M | ||||||
| Royalty & Licensing Revenues | — | — | — | — | ||||||
| Royalty Revenues | — | — | — | — | ||||||
| Royalty Revenue | — | — | — | — | ||||||
| Royalty | — | — | — | — | ||||||
| Licensing Revenue | — | — | — | — | ||||||
| Licensing | — | — | — | — | ||||||
| Total | $667.24M | $607.52M | $661.82M | $718.95M |
In fiscal 2025, which ended December 31, 2025, the 9 revenue lines Supernus Pharmaceuticals, Inc. reported in this breakdown added up to $718.95M. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $661.82M reported that year. Qelbree was the largest revenue line, at $304.65M or 42.4% of the total, followed by Gocovri ($146.82M, 20.4%) and Collaboration Revenue (Zurzuvae) ($53.00M, 7.4%). Together, the two largest revenue lines made up 62.8% of this total.
Compared with fiscal 2024, Royalty, Licensing, & Other Revenues grew the fastest, rising 63.4% to $39.42M. Oxtellar Xr fell the most, down 59.1% to $40.70M. Because revenue lines were added or dropped between the two years, part of this reflects how Supernus Pharmaceuticals, Inc. regrouped its reporting.
Collaboration Revenue (Zurzuvae) (fiscal 2025), Royalty, Licensing, & Other Revenues (fiscal 2023) and Onapgo (fiscal 2025) were first reported as separate revenue lines during this period. The table also keeps 7 revenue lines that Supernus Pharmaceuticals, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 7 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Supernus Pharmaceuticals, Inc.'s annual filings.
Supernus Pharmaceuticals, Inc. (SUPN) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Qelbree, with $304.65M or 42.4% of the total, followed by Gocovri at $146.82M (20.4%).
Qelbree was Supernus Pharmaceuticals, Inc.'s largest revenue line in fiscal 2025, with $304.65M in revenue, 42.4% of the $718.95M reported across its 9 revenue lines.
Every figure is taken from Supernus Pharmaceuticals, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2016 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.